43 assets in Colon Adenocarcinoma

Therapeutic assets addressing Colon Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fluorouracilum Colon Adenocarcinoma	Merck Sharp & Dohme LLC	P3	BBB (77)
Irinotecan Colon Adenocarcinoma	Sun Yat-sen University	P3	BBB (76)
Oxaliplatin Colon Adenocarcinoma	Sun Yat-sen University	P3	BBB (76)
Cetuximab Colon Adenocarcinoma	Merck Sharp & Dohme LLC	P3	BB (70)
Nivolumab Colon Adenocarcinoma	IFOM ETS - The AIRC Institute of Molecular Oncology	P3	BB (70)
Capecitabine Colon Adenocarcinoma	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	P3	BB (68)
Encorafenib Colon Adenocarcinoma	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P2/3	BB (67)
Pertuzumab Colon Adenocarcinoma	IFOM ETS - The AIRC Institute of Molecular Oncology	P3	BB (67)
Panitumumab Colon Adenocarcinoma	IFOM ETS - The AIRC Institute of Molecular Oncology	P3	BB (66)
Regorafenib Colon Adenocarcinoma	City of Hope Medical Center	P3	BB (66)
Trastuzumab Colon Adenocarcinoma	IFOM ETS - The AIRC Institute of Molecular Oncology	P3	BB (66)
Ipilimumab Colon Adenocarcinoma	IFOM ETS - The AIRC Institute of Molecular Oncology	P3	BB (64)
Levofolinic Acid Colon Adenocarcinoma	Merck Sharp & Dohme LLC	P3	BB (64)
Tipiracil Colon Adenocarcinoma	Academic and Community Cancer Research United	P2	BB (64)
Trifluridine Colon Adenocarcinoma	Academic and Community Cancer Research United	P2	BB (64)
Atezolizumab Colon Adenocarcinoma	Georgetown University	P3	B (60)
Balstilimab Colon Adenocarcinoma	City of Hope Medical Center	P2	B (60)
Botensilimab Colon Adenocarcinoma	City of Hope Medical Center	P2	B (60)
Calderasib Colon Adenocarcinoma	Merck Sharp & Dohme LLC	P3	B (60)
Pembrolizumab Colon Adenocarcinoma	University College, London	P2	B (60)
Trastuzumab Deruxtecan Colon Adenocarcinoma	Gruppo Oncologico del Nord-Ovest	P2	B (60)
Cabozantinib Colon Adenocarcinoma	University of Colorado, Denver	P2	CCC (53)
Fentanyl Colon Adenocarcinoma	University of Kansas Medical Center	P2	CCC (53)
Propofol Colon Adenocarcinoma	University of Kansas Medical Center	P2	CCC (53)
Sevoflurane Colon Adenocarcinoma	University of Kansas Medical Center	P2	CCC (53)
Tislelizumab Colon Adenocarcinoma	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	P2	CCC (53)
Tolecizumab Colon Adenocarcinoma	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	P2	CCC (53)
Tucatinib Colon Adenocarcinoma	Academic and Community Cancer Research United	P2	CCC (53)
Tucidinostat Colon Adenocarcinoma	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	P2	CCC (53)
Abemaciclib Colon Adenocarcinoma	M.D. Anderson Cancer Center	P1/2	CCC (48)
Eb-Duo-Car-Nk-Cea/Gcc Colon Adenocarcinoma	Beijing Biotech	P1/2	CCC (48)
hlx43 Colon Adenocarcinoma	Shanghai Henlius Biotech	P1/2	CCC (48)
Pimurutamab Colon Adenocarcinoma	Shanghai Henlius Biotech	P1/2	CCC (48)
Serplulimab Colon Adenocarcinoma	Shanghai Henlius Biotech	P1/2	CCC (48)
SX682 Colon Adenocarcinoma	M.D. Anderson Cancer Center	P1/2	CCC (48)
Temuterkib Colon Adenocarcinoma	M.D. Anderson Cancer Center	P1/2	CCC (48)
Polypepi1018 Colon Adenocarcinoma	Mayo Clinic	P1	CC (47)
atp128 Colon Adenocarcinoma	Amal Therapeutics	P1	CC (43)
Ceralasertib Colon Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (43)
Ezabenlimab Colon Adenocarcinoma	Amal Therapeutics	P1	CC (43)
Tas-102 Colon Adenocarcinoma	University of California, Irvine	P1	CC (43)
Vsv-Gp128 Colon Adenocarcinoma	Amal Therapeutics	P1	CC (43)
Ropidoxuridine Colon Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (41)